Lv11
40 积分 2024-11-21 加入
Randomized, double-blind, placebo-controlled phase 2a study assessing the efficacy and safety of felzartamab for IgA nephropathy
3小时前
待确认
Lysophosphatidic acid promotes colitis-associated intestinal fibrosis by suppressing autophagy via LPAR3/ AMPK/mTOR pathway
5天前
已完结
Necessity of Lysophosphatidic Acid Receptor 1 for Development of Arthritis
6天前
已完结
Lysophosphatidic acid receptor inhibition as a new multipronged treatment for rheumatoid arthritis
7天前
已完结
LPA1 Receptor Activation Promotes Renal Interstitial Fibrosis
8天前
已完结
Alternative Complement Pathway Inhibition with Iptacopan in IgA Nephropathy
19天前
已完结
Alternative Complement Pathway Inhibition With Iptacopan for the Treatment of C3 Glomerulopathy-Study Design of the APPEAR-C3G Trial
19天前
已完结
The role of the alternative pathway of complement activation in glomerular diseases
19天前
已完结
Epidemiology of IgA Nephropathy: A Global Perspective
19天前
已完结
Pharmacokinetics of Fipaxalparant, a Small‐Molecule Selective Negative Allosteric Modulator of Lysophosphatidic Acid Receptor 1, and the Effect of Food in Healthy Volunteers
1个月前
已完结
皖公网安备34019202002308
